Tag: blood screening market outlook

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Blood Screening Market Growth From $3.84 Billion In 2026 To $5.93 Billion By 2030 At A CAGR Of 11.5%

The blood screening market has experienced substantial expansion lately. Projections indicate a rise from $3.44 billion in 2025 to $3.84 billion in 2026, reflecting a compound annual growth rate of 11.6%. Factors contributing to this past growth include more stringent regulatory screening mandates, an increase in blood donation quantities, a higher incidence of transfusion-transmitted infections, the proliferation of centralized blood banking facilities, and the widespread implementation of ELISA testing methods.

The global blood screening market is poised for significant expansion, projecting to reach $5.93 billion by 2030 with a compound annual growth rate of 11.5%. This upward trajectory is primarily fueled by escalating investments in sophisticated screening technologies, a heightened need for prompt and precise diagnostic solutions, broader acceptance of molecular testing methodologies, the increasing incorporation of AI for data analytics, and a stronger emphasis on international blood safety protocols. Key developments anticipated during this period involve a greater uptake of nucleic acid testing, a surge in demand for high-volume screening systems, more widespread utilization of automated blood screening equipment, the proliferation of screening platforms integrated with software, and an intensified concentration on ensuring transfusion safety.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp

Blood Screening Market Opportunity Drivers: What Is Creating New Revenue Potential?

The escalating incidence of long-term health conditions is anticipated to be a significant catalyst for the expansion of the blood screening sector. Chronic illnesses, characterized as persistent ailments that are generally treatable rather than curable, necessitate ongoing management of both medical interventions and the lifestyle adjustments they demand. Blood screening plays a crucial role in ensuring donor-recipient blood type compatibility during transfusions, a procedure often essential for managing various chronic conditions such as autoimmune disorders, blood-related diseases, and all types of cancer. Globally, the World Health Organization reported in September 2023 that non-communicable diseases, or chronic conditions, account for a substantial 74% of the 41 million annual deaths worldwide. Consequently, this rising burden of chronic diseases is directly contributing to the advancement of the blood screening market.

Blood Screening Market Segmentation And Category Breakdown

The blood screening market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Software And Services

2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)

3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Reagents And Kits: Diagnostic Reagents, Testing Kits

2) By Instruments: Automated Analyzers, Manual Testing Equipment

3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services

Blood Screening Market Innovation Trends Driving Future Development

In the blood screening market, leading corporations are advancing techniques like liquid biopsy, aiming to refine early cancer identification, enhance treatment oversight, and facilitate customized medical treatments. Liquid biopsy represents a low-impact examination, scrutinizing blood or alternative bodily fluids for the presence of cancerous cells or tumor-derived genetic material. Illustratively, a notable development occurred in November 2023 when Guardant Health, Inc., a biotechnology firm situated in the United States, introduced its Shield blood-based screening assays. This Shield test is designed to examine cell-free DNA (cfDNA) circulating within the bloodstream, a marker that can signal the existence of colon tumors or precancerous lesions, by specifically identifying modifications in DNA fragments originating from malignant cells and subsequently released into the blood.

Blood Screening Market Competitive Analysis Of Major Industry Participants

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

Access The Complete Blood Screening Market Report:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

#Blood Screening Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Blood Screening Market By 2030 Based On Its 2026 Value?

The blood stream infection testing market size has witnessed substantial growth in recent years. It is anticipated to increase from $8.49 billion in 2025 to $9.5 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.9%. The historical expansion of this market can be ascribed to elements such as increasing incidence of bloodstream infections, rising hospital-acquired infection rates, expansion of clinical microbiology laboratories, adoption of automated diagnostic instruments, and growing awareness of sepsis management.

The market for blood stream infection testing is projected to experience swift expansion over the coming years, with its size forecast to reach $14.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. Factors driving this growth during the projection period include a heightened need for quick diagnostic results, the increasing use of molecular diagnostics within hospitals, the broadening scope of personalized infection management, increased financial outlays in sophisticated laboratory infrastructure, and the growing incorporation of AI-powered diagnostic instruments. Key trends anticipated for the forecast timeframe encompass the wider acceptance of rapid molecular diagnostic assays, an uptick in the deployment of automated blood culture systems, the progressive inclusion of antimicrobial susceptibility testing, an enlargement of multiplex pathogen detection panels, and a heightened emphasis on the prompt diagnosis of sepsis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp

What Core Drivers Are Transforming The Blood Screening Market?

The rising occurrence of infectious diseases is projected to stimulate the expansion of the blood stream infection testing market in the future. These diseases are defined as illnesses resulting from pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites. The rates of infectious diseases are escalating due to several factors, including increased global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Bloodstream infection testing is vital in managing infectious diseases for diagnosing and identifying pathogens responsible for sepsis and other severe infections, which enables targeted and effective treatment. For instance, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from about 7.5 million in 2022, positioning tuberculosis as the leading infectious disease killer. Consequently, the growing prevalence of infectious diseases is a primary driver for the blood stream infection testing market.

What Are The Major Segment Categories Within The Blood Screening Market?

The blood screening market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Software And Services

2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)

3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Reagents And Kits: Diagnostic Reagents, Testing Kits

2) By Instruments: Automated Analyzers, Manual Testing Equipment

3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services

What Trends Are Influencing The Future Of The Blood Screening Market?

Leading companies in the bloodstream infection testing market are concentrating on integrating advanced technologies, such as machine learning-powered host-response diagnostics, to improve rapid detection, support clinical decision-making, and potentially enhance patient management. Host-response diagnostics analyze a patient’s immune system through gene expression signatures in blood samples, utilizing artificial intelligence (AI)-derived algorithms to determine the presence, type, and probable severity of an infection in real time, which helps clinicians make quicker and more precise treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, obtained clearance from the US Food and Drug Administration for TriVerity, a machine-learning-based molecular blood test designed to assist in the swift evaluation of patients with suspected acute infections or sepsis. This test measures 29 immune-related mRNAs and provides AI-generated scores indicating the likelihood of bacterial infection, viral infection, and the risk of severe illness, with results typically available in about 30 minutes. TriVerity supports clinical decision-making by decreasing diagnostic uncertainty, facilitating timely targeted therapy, and helping to optimize hospital resource utilization when employed alongside standard clinical evaluation and laboratory findings.

Which Organizations Are Operating Within The Blood Screening Market?

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

Access The Complete Blood Screening Market Report:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Which Region Has The Strongest Presence In The Blood Screening Market?

North America was the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Blood Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=9047&type=smp

Browse Through More Reports Similar to the Global Blood Screening Market 2026, By The Business Research Company

Drug Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-screening-global-market-report

Blood Culture Tests Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

Bleeding Disorder Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Blood Screening Market Progress Between 2026 And 2030?

The blood screening market has witnessed substantial growth over recent years. Its size is projected to expand from $3.44 billion in 2025 to $3.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.6%. The market’s historical growth can be attributed to several factors, including more stringent regulatory screening requirements, an increase in blood donation volumes, the rising prevalence of transfusion-transmitted infections, the development of centralized blood banks, and the adoption of ELISA-based testing.

The blood screening market is anticipated to experience substantial growth over the next few years. It is projected to reach $5.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.5%. This expansion during the forecast period can be attributed to factors such as increased investments in advanced screening technologies, a rising demand for rapid and accurate diagnostics, the broadening adoption of molecular testing, the increasing integration of AI-driven data analysis, and a heightened focus on global blood safety standards. Prominent trends for the forecast period include the growing uptake of nucleic acid testing technologies, an escalating demand for high-throughput screening systems, the expanding utilization of automated blood screening instruments, the proliferation of software-integrated screening platforms, and an intensified emphasis on transfusion safety.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Which Important Drivers Are Guiding The Blood Screening Market Growth?

The rising incidence of chronic diseases is anticipated to drive the expansion of the blood screening market. These are long-lasting medical conditions or illnesses that, while often manageable, lack a cure and necessitate adaptation to ongoing treatment and its requirements. Blood screening plays a crucial role in ensuring compatibility between donor and recipient blood types during transfusion procedures. Such transfusions are frequently essential in managing various chronic conditions, including autoimmune disorders, blood-related diseases, and diverse forms of cancer. A notable example is the statistic from September 2023, where the World Health Organization, a specialized UN agency located in Switzerland, reported 41 million deaths globally each year attributable to non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of total deaths. Consequently, the growing occurrence of chronic diseases is a significant catalyst for the growth of the blood screening market.

How Is The Blood Screening Market Segmented Across Different Segment Categories?

The blood screening market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Software And Services

2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)

3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Reagents And Kits: Diagnostic Reagents, Testing Kits

2) By Instruments: Automated Analyzers, Manual Testing Equipment

3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services

What Trends Are Influencing The Evolution Of The Blood Screening Market?

Key players in the blood screening market are advancing technologies like liquid biopsy to enhance the early detection of cancer, improve how treatments are monitored, and enable individualized medicine approaches. A liquid biopsy is a minimally invasive procedure that scrutinizes blood or other bodily fluids to identify cancer cells or tumor-derived genetic material. For instance, in November 2023, Guardant Health, Inc., a US-based biotechnology company, launched its Shield blood-based screening tests. The Shield test analyzes cell-free DNA (cfDNA) present in the bloodstream, which can indicate colorectal tumors or precancerous growths. It specifically searches for changes in DNA fragments that cancer cells release into the blood.

Which Organizations Play A Role In The Blood Screening Market Landscape?

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

Get The Full Blood Screening Market Report:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Which Region Has The Greatest Market Share In The Blood Screening Market?

North America was the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Blood Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Browse Through More Reports Similar to the Global Blood Screening Market 2026, By The Business Research Company

Bleeding Disorder Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Drug Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-screening-global-market-report

Blood Culture Tests Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Blood Screening Market Expected To Change Between 2026 And 2030?

The blood screening market has seen swift expansion in recent years. It is forecast to grow from $3.44 billion in 2025 to $3.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.6%. Historically, this growth can be attributed to factors such as increasingly strict regulatory screening mandates, an increase in blood donation volumes, a rising incidence of transfusion-transmitted infections, the establishment of centralized blood banks, and the embrace of ELISA-based testing.

The blood screening market is projected to experience rapid growth in the upcoming years. Its valuation is set to reach $5.93 billion by 2030, progressing at a compound annual growth rate (CAGR) of 11.5%. This expansion during the forecast period is attributed to increased investments in advanced screening technologies, a rising demand for rapid and accurate diagnostics, the broadening adoption of molecular testing, the growing integration of AI-driven data analysis, and an elevated focus on global blood safety standards. Significant trends foreseen in this period include the increasing uptake of nucleic acid testing technologies, an escalating demand for high-throughput screening systems, the expanding utilization of automated blood screening instruments, the proliferation of software-integrated screening platforms, and an enhanced emphasis on transfusion safety.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp

Which Economic Or Industry Drivers Are Impacting The Blood Screening Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the blood screening market. Chronic diseases are long-term conditions or illnesses that are typically manageable but not curable, demanding adjustment to both the therapy used to treat the condition and its requirements. Blood screening diligently matches the compatibility between the donor’s and recipient’s blood types during transfusions. Blood transfusions are frequently essential as part of medical treatments for numerous chronic diseases, including autoimmune diseases, hematological disorders, and all forms of cancers. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths globally, accounting for 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year. Therefore, the growing prevalence of chronic diseases is driving the growth of the blood screening market.

How Is The Blood Screening Market Structured Across Different Segments?

The blood screening market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Software And Services

2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)

3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Reagents And Kits: Diagnostic Reagents, Testing Kits

2) By Instruments: Automated Analyzers, Manual Testing Equipment

3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services

Which Trends Are Impacting The Growth Of The Blood Screening Market?

Leading companies active in the blood screening market are developing technologies such as liquid biopsy to enhance the early detection of cancer, improve the monitoring of treatments, and enable personalized medicine approaches. A liquid biopsy is a minimally invasive test that examines blood or other body fluids to identify cancer cells or genetic material from tumors. For instance, in November 2023, Guardant Health, Inc., a US-based biotechnology company, introduced its Shield blood-based screening tests. The Shield test analyzes cell-free DNA (cfDNA) present in the bloodstream, which can indicate the presence of colorectal tumors or precancerous growths. It specifically looks for alterations in DNA fragments that are released into the blood from cancer cells.

Which Major Players Dominate The Blood Screening Market?

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

Read the full blood screening market report here:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

What Are The Top-Performing Regions Within The Blood Screening Market?

North America was the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Blood Screening Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9047&type=smp

Browse Through More Reports Similar to the Global Blood Screening Market 2026, By The Business Research Company

Drug Screening Global Market Report

https://www.thebusinessresearchcompany.com/report/drug-screening-global-market-report

Blood Culture Tests Global Market Report

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

Bleeding Disorder Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model